Skip to main content
ALLIANCE PHARMA PLC logo

ALLIANCE PHARMA PLC — Investor Relations & Filings

Ticker · APH ISIN · GB0031030819 LEI · 213800RYIWZA4Q5WPZ13 IL Wholesale and retail trade
Open in API
Filings indexed 492 across all filing types
Latest filing 2025-05-15 Delisting Announcement
Country GB United Kingdom
Listing IL APH

About ALLIANCE PHARMA PLC

https://www.alliancepharmaceuticals.com/

Alliance Pharma PLC is an international specialty pharmaceutical company with a primary focus on consumer healthcare. The company's business model is centered on the acquisition, licensing, and marketing of a portfolio of consumer health products and prescription medicines. It operates globally, investing in its key brands to empower consumers to improve their health and wellbeing. A core part of its strategy is the ongoing development to become a high-performing consumer healthcare company.

Recent filings

Filing Released Lang Actions
Cancellation of Trading
Delisting Announcement Classification · 99% confidence The document is an RNS announcement (RNS Number : 7061I) dated 15 May 2025. The content explicitly discusses a 'RECOMMENDED ACQUISITION' of Alliance Pharma PLC by Aegros Bidco Limited, implemented via a 'Scheme of Arrangement under Part 26 of the Companies Act 2006'. It also announces the 'CANCELLATION OF TRADING' of Alliance shares. This subject matter—a takeover/acquisition proposal and subsequent scheme of arrangement—falls directly under the definition of M&A Activity (TAR). Although it is an announcement, the core subject is the transaction itself, which is more specific than a general Regulatory Filing (RNS) or Report Publication Announcement (RPA). Since the document details the mechanics and final steps of a takeover, TAR is the most appropriate classification.
2025-05-15 English
Scheme of Arrangement Becomes Effective
AGM Information Classification · 99% confidence The document is an RNS announcement (RNS Number : 6113I) from Alliance Pharma PLC, dated 14 May 2025. The primary subject is the 'RECOMMENDED ACQUISITION OF ALLIANCE PHARMA PLC BY AEGROS BIDCO LIMITED' and specifically announces that the 'SCHEME OF ARRANGEMENT BECOMES EFFECTIVE'. This announcement details the final steps of a takeover, including settlement of consideration, suspension/cancellation of trading, and director resignations. Since this is a formal announcement regarding a significant corporate action (a takeover/acquisition) filed via the Regulatory News Service (RNS), and it does not fit the specific definitions for M&A Activity (TAR) which usually covers the proposal/bid itself, or Director's Dealing (DIRS), or Capital Change (SHA), the most appropriate general classification for a major regulatory announcement that is not a core financial report (like 10-K or IR) or a specific corporate event announcement (like DIV or DVA) is the general Regulatory Filings category (RNS). Although it relates to M&A, the content is the final regulatory notification of the scheme's effectiveness, which often defaults to RNS if TAR is reserved for the initial bid documents. Given the RNS header and the nature of the announcement (a final step in a takeover process), RNS is the best fit as a broad regulatory filing.
2025-05-14 English
COURT SANCTION OF THE SCHEME OF ARRANGEMENT
M&A Activity Classification · 99% confidence The document is an RNS announcement dated May 12, 2025, detailing the 'RECOMMENDED ACQUISITION' of Alliance Pharma PLC by Aegros Bidco Limited via a Scheme of Arrangement under Part 26 of the Companies Act 2006. It specifically mentions the 'COURT SANCTION OF THE SCHEME OF ARRANGEMENT' and subsequent steps like option exercises, share allotment, and AIM delisting/cancellation. The text explicitly references compliance with the 'Takeover Code' and Rule 2.9, which governs takeover offers. This content directly relates to a merger or takeover proposal. Therefore, the appropriate classification is M&A Activity (TAR).
2025-05-12 English
Notification of Major Holdings
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is a regulatory requirement for shareholders to disclose when their voting rights in a company cross certain thresholds. This is a classic 'Major Shareholding Notification' filing, which corresponds to the code MRQ.
2025-05-01 English
Notification of Major Holdings
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is the regulatory standard in the UK for disclosing changes in significant share ownership (crossing thresholds). It explicitly details the issuer (Alliance Pharma PLC), the person subject to the notification (Slater Investments), and the change in voting rights percentage. This aligns perfectly with the definition of a Major Shareholding Notification.
2025-04-29 English
Notification of Major Holdings
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details the acquisition or disposal of voting rights by Slater Investments in Alliance Pharma PLC, crossing a specific threshold. This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2025-04-29 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.